Caldwell Neil A, Townsend Ceri
Department of Pharmacy, Wirral University Teaching Hospital NHS Foundation Trust, Wirral, UK.
Department of Paediatrics, Wirral University Teaching Hospital, Wirral, UK.
Arch Dis Child Educ Pract Ed. 2016 Feb;101(1):38-42. doi: 10.1136/archdischild-2015-308780. Epub 2015 Oct 28.
Respiratory syncytial virus (RSV) is a predictable, seasonal disease with significant morbidity and mortality in children below 24 months. Prophylaxis, which decreases hospitalisation in those most vulnerable to the disease, has been available since 1998. Pharmacological prophylaxis is however, expensive and requires good infrastructure to deliver. It is out of reach for many patients in low-income and middle-income countries where mortality is highest. This article looks at the pathophysiology and risk factors for RSV. It also outlines what agents are currently available for prophylaxis and prevention.
呼吸道合胞病毒（RSV）是一种具有可预测性的季节性疾病，对24个月以下儿童具有较高的发病率和死亡率。自1998年以来，已有预防措施，可降低最易感染该疾病人群的住院率。然而，药物预防成本高昂，且需要良好的基础设施来实施。对于死亡率最高的低收入和中等收入国家的许多患者来说，这是他们无法企及的。本文探讨了RSV的病理生理学和危险因素。它还概述了目前可用于预防的药物。
